Journal Articles on Mesothelioma: 'Epithelioid' Category
Epitheliod mesothelioma makes up between 50% and 70% of all diagnosed cases of mesothelioma; it also tends to have the best prognosis.
March 6th, 2008. Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies
We have further exploited the internalizing function of these scFvs to achieve targeted intracellular drug delivery to mesothelioma cells. We showed that scFv-targeted immunoliposomes were efficiently and specifically taken up by both epithelioid and sarcomatous mesothelioma cells, but not control cells, and immunoliposomes encapsulating the small-molecule drug topotecan caused targeted killing of both types of mesothelioma cells in vitro.
March 5th, 2008. Use of immunocytochemical assays in the study of exudates from serous cavities in the practical work of a laboratory
In 31 cases, adenogenic carcinoma metastases to the serous cavities were typified by an immunopositive reaction to CEA, Ber-EP4, EMA, and cytokeratins and a negative reaction to calretinin, mesothelin, and thrombomodulin. There was occasionally a positive reaction to CD-15 and vimentin.
February 29th, 2008. New diagnostic markers for malignant pleural mesothelioma
Despite a good sensitivity, osteopontin has a low specificity for mesothelioma diagnosis. However, there is not enough data yet to propose guidelines on the use of these markers in a day to day practice.
February 28th, 2008. Unusual Features of Malignant Pleural Mesothelioma Metastatic to the Mediastinal Lymph Nodes
In summary, MPM may present as mediastinal lymphadenopathy with metastases or it may be a concurrent neoplasm with other malignancies or shows an unusual immunohistochemical staining pattern. Caution should be used when diagnosing mesothelial cell inclusions in MLNs.
February 28th, 2008. Pleural mesothelioma: diagnostic problems and evaluation of prognostic factors
Conclusion: MPM is an increasing disaster in Egypt which is underestimated and neglected. A panel of immunohistochemical markers should be used for proper evaluation. p27 has proven to be a potential biologic prognostic marker for mesothelioma and more studies as regard its significance are recommended on a larger number.
February 19th, 2008. Malignant pleural mesothelioma: multidisciplinary experience in a public tertiary hospital
Conclusions: In the cases studied, an integrated multidisciplinary approach was used, and a highly complex hospital infrastructure was available for the diagnosis and treatment of MPM, as recommended in the literature. However, the mean survival was only 11 months, reflecting the aggressiveness of the disease.
Posted in Biphasic or Mixed, Chemotherapy, Diagnosis & Differentiation, Epithelioid, Full Archive, General, Pleural, Pleural Biopsy, Pneumonectomy, Radiation, Sarcomatoid, Surgery, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma:, thoracoscopy | No Comments »
February 11th, 2008. Expression of mesothelin as a potential diagnostic marker in mesothelioma
None of the sarcomatoid mesotheliomas exhibited positivity for this marker, nor was any reactivity seen in the spindle cell component of the biphasic mesotheliomas. These findings indicate that, in some instances, mesothelin immunostaining can assist in the diagnosis of mesothelioma.
January 29th, 2008. Xanthomatous Pleuritis Mimicking Mesothelioma
Our patient quickly recovered with steroid therapy and is without recurrence 18 months later. This case demonstrates the utility and nuances of medical thoracoscopy in a perplexing case of xanthomatous pleuritis.
January 3rd, 2008. Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells
In addition, a splice variant transcript of mesothelin (variant 3) was detected in these MPM cell lines, in accordance with the release of a secreted part of the protein. Our results indicate that both mechanisms could be implicated in soluble mesothelin production by epithelioid mesothelioma cells.
December 29th, 2007. Podoplanin is a Better Immunohistochemical Marker for Sarcomatoid Mesothelioma Than Calretinin
Overall sensitivities and pecificities were 84% and 99% for antipodoplanin, and 86% and 96% for D2-40. These findings suggest that cytoplasmic podoplanin expression may be useful in the diagnosis of sarcomatoid mesothelioma, although it should be used with caution on biopsy material.
December 25th, 2007. Localised malignant pleural mesothelioma: a separate clinical entity requiring aggressive local surgery
Conclusion: Our results suggest that surgery is indicated in treating localised MPM even in T4 (diffuse chest wall involvement) tumours but pleuropneumonectomy is not necessary. These tumours seem to have a different biological behaviour compared to diffuse MPM but further research, including identification of possibly different biological markers is necessary.
Posted in Biphasic or Mixed, Epithelioid, Full Archive, Pleural, Pleurectomy/decortication, Pneumonectomy, Sarcomatoid, Surgery, Survival, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
December 19th, 2007. Integrated FDG PET-CT imaging improves staging in malignant pleural mesothelioma
Conclusions: PET-CT seems to be a valuable tool in staging of MPM and leads to discordant findings in almost every second patient compared to CT alone. In many cases these differences are clinically relevant and have therapeutic consequences.
November 17th, 2007. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: A phase II study of the Southwest Oncology Group (SWOG 9810)
Conclusions: Cisplatin–gemcitabine combination chemotherapy has modest activity with an acceptable toxicity profile, as first line treatment for patients with malignant mesothelioma.
November 3rd, 2007. Novel expression of kallikreins, kallikrein-related peptidases and kinin receptors in human pleural mesothelioma
KRP/hK2, 6, 8 and 9 were also expressed in the cytoplasm and nuclei of mesothelioma cells, whereas KRP/hK5 and hK7 showed predominantly cytoplasmic localisation. This is a first report, but further studies are required to determine whether these proteins have a functional role in the pathogenesis of mesothelioma and/or may be potential biomarkers for pleural mesothelioma.
Posted in Biphasic or Mixed, Diagnosis & Differentiation, Epithelioid, Full Archive, New & Novel, Pleural, Sarcomatoid, Serum Marker/Blood Test, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
October 3rd, 2007. Apparent spontaneous complete regression of a multifocal malignant mesothelioma of the pleura
This case demonstrates that this tumour may, very rarely, regress spontaneously, with no recurrence for many years. A greater knowledge of the underlying immune mechanisms would aid future management of this and other tumours.
September 22nd, 2007. Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma
Conclusions: Pleural biopsy performed using thoracoscopy is considered to be the cornerstone of the diagnosis and pleural staging of MPM. However, this procedure appears to be less efficient in diagnosing the histologic subtype as either epithelial or biphasic.
August 2nd, 2007. h-Caldesmon, Calretinin, Estrogen Receptor, and Ber-EP4: A Useful Combination of Immunohistochemical Markers for Differentiating Epithelioid Peritoneal Mesothelioma From Serous Papillary Carcinoma of the Ovary
3%). The relationship between the values of sensitivity and specificity of each marker using receiver operating characteristic analysis permitted the identification of h-CD, calretinin, ER, and Ber-EP4 as the markers with the best performance in differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary.
June 19th, 2007. Establishment and characterization of two distinct malignant mesothelioma cell lines with common clonal origin
Remarkably, one xenograft from MM-Z03E revealed overexpression of p53 and widely invasive growth. In conclusion, both cell lines are useful in vivo and in vitro model systems to study the underlying genetic mechanisms of biphasic differentiation in MM, which can be of certain value considering the increasing relevance of assessing MM tumor biology for the clinical management of this disease.
June 15th, 2007. Primary omental Gastrointestinal stromal tumor (GIST)
Conclusion: Our case demonstrated a weak immunohistochemical expression of c-kit (CD117) and a point mutation in PDGFRA exon 12 resulting in an Asp for Val561 substitution. Imatinib therapy as an adjuvant to complete resection has been carried out safely. Because of the rarity of primary omental GISTs, it is inevitable to analyze accumulating data from case reports for a better and more detailed understanding of primary omental GISTs.
|
|  |
